1. Dr. Nikhil Munshi. Multiple myeloma expert. Biography. 0
Dr. Nikhil Munshi, MD, explains the latest advances in blood cancer treatment. He is a professor at Harvard Medical School and Director at Dana Farber...
▶⏸
2. Multiple myeloma. Progress and challenges of treatment. 1
Dr. Nikhil Munshi, MD, explains the remarkable progress in treating this complex blood cancer. He highlights key advances in genomic understanding, the tumor microenvironment, and...
Dr. Nikhil Munshi, MD, explains the key genetic changes that drive disease progression. He details how specific chromosomal abnormalities occur very early in MGUS and...
▶⏸
4. Multiple myeloma and bone marrow microenvironment. ‘Seed and soil’ concept in cancer progression. 3
Dr. Nikhil Munshi, MD, explains the critical role of the bone marrow microenvironment in cancer progression. He details the "seed and soil" concept where myeloma...
▶⏸
5. Multiple myeloma and gene expression profiling. Intraclonal heterogeneity. 4
Dr. Nikhil Munshi, MD, explains intraclonal heterogeneity. This is a core feature of cancer. Tumor cells acquire new genetic changes as they grow. This creates...
▶⏸
6. Multiple myeloma. Risk stratification criteria to select the best treatment for each patient. 5
Dr. Nikhil Munshi, MD, explains how risk stratification guides treatment selection. He details the evolution of criteria from the Durie-Salmon system to modern cytogenetic and...
▶⏸
7. Autologous stem cell transplantation in multiple myeloma. 6
Dr. Nikhil Munshi, MD, explains how autologous stem cell transplantation remains a frontline therapy. He discusses the recent DFCI study results. Transplant provides a significant...
▶⏸
8. How to select drug combinations for multiple myeloma treatment? 7
Dr. Nikhil Munshi, MD, explains how treatment has evolved. He details the shift from two-drug to three and four-drug combinations. These new regimens achieve near...
▶⏸
9. Chimeric antigen receptor T-cell therapy in multiple myeloma. CAR T-cell immunotherapy. 8
Dr. Nikhil Munshi, MD, explains how CAR T-cell therapy is revolutionizing treatment. He describes unprecedented response rates in late-stage patients.
Dr. Nikhil Munshi, MD, explains how minimal residual disease (MRD) evaluation is a critical prognostic factor. He details the two state-of-the-art methods for MRD testing:...
▶⏸
11. Castleman Disease. Subtypes and treatment options. 10
Dr. Nikhil Munshi, MD, explains Castleman disease subtypes and treatment options. He details the differences between localized and multicentric forms of this rare lymphoproliferative disorder....
▶⏸
12. Future in multiple myeloma treatment. When will it be a ‘curable disease’? 11
Dr. Nikhil Munshi, MD, explains how a significant proportion of patients are effectively cured today. He discusses the evolution of treatment and the future role...
▶⏸
13. Multiple myeloma. FAQ: Immunization, Vitamin D and bone health, quality of life. 12
Dr. Nikhil Munshi, MD, explains key patient concerns. He addresses COVID-19 vaccination and monoclonal antibody prophylaxis for immunocompromised patients.
▶⏸
14. Multiple myeloma. Patient’s story: elderly woman and ‘last hope’ CAR T-cell therapy. 13
Dr. Nikhil Munshi, MD, explains the power of novel treatments for relapsed disease. He shares a compelling patient story of an elderly woman who achieved...
▶⏸
15. Multiple myeloma. Message of hope for cancer treatment and for life. 14
Dr. Nikhil Munshi, MD, delivers a powerful message of hope for cancer patients. He explains that despite global challenges, incredible treatment advances provide numerous options....
Refine your treatment plan with a panel of top doctors who precisely fit your case.
